Eli Lilly in charts: Obesity and diabetes portfolio drives growth in Q3 with Mounjaro +109% and Zepbound +185% Y/Y

To ensure this doesn’t happen in the future, please enable JavaScript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled, you may be blocked from proceeding. Please disable your ad-blocker and refresh the page.
https://seekingalpha.com/news/4511204-eli-lilly-in-charts-obesity-and-diabetes-portfolio-drives-growth-in-q3-with-mounjaro-109-and-zepbound-185-yy?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news

Leave a Reply

Your email address will not be published. Required fields are marked *

*